Zobrazeno 1 - 9
of 9
pro vyhledávání: '"James N. Atkins"'
Autor:
Norman Wolmark, V. Craig Jordan, Leslie G. Ford, Worta McCaskill-Stevens, Steven E. Reis, Patricia A. Ganz, Carolyn D. Runowicz, Joan James, Richard G. Margolese, André Robidoux, James L. Wade, Eduardo R. Pajon, Louis Fehrenbacher, Therese B. Bevers, James N. Atkins, Reena S. Cecchini, Walter M. Cronin, D. Lawrence Wickerham, Joseph P. Costantino, Victor G. Vogel
Perspectives on this Article from Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a9f388966e431da8a9096898638207b
https://doi.org/10.1158/1940-6207.22523329.v1
https://doi.org/10.1158/1940-6207.22523329.v1
Autor:
Deanna L. Kroetz, Kouros Owzar, Alan P. Venook, Mark J. Ratain, Federico Innocenti, Howard L. McLeod, William Kevin Kelly, Susan Halabi, Hope S. Rugo, James N. Atkins, Heinz-Josef Lenz, Howard S. Hochster, Donna Niedzwiecki, Michiaki Kubo, Yukihide Momozawa, Paula N. Friedman, Fei Shen, Bryan P. Schneider, Bert H. O’Neil, Chen Jiang, Flora Mulkey, Megan Li
Purpose: Bevacizumab is a VEGF-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of multiple cancers. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e99a814a31f502415951927ae4a4f7e
https://doi.org/10.1158/1078-0432.c.6525887
https://doi.org/10.1158/1078-0432.c.6525887
Autor:
Deanna L. Kroetz, Kouros Owzar, Alan P. Venook, Mark J. Ratain, Federico Innocenti, Howard L. McLeod, William Kevin Kelly, Susan Halabi, Hope S. Rugo, James N. Atkins, Heinz-Josef Lenz, Howard S. Hochster, Donna Niedzwiecki, Michiaki Kubo, Yukihide Momozawa, Paula N. Friedman, Fei Shen, Bryan P. Schneider, Bert H. O’Neil, Chen Jiang, Flora Mulkey, Megan Li
Supplemental Methods, Tables and Figures Table S1. Analyzed candidate genes Table S2. Gene sets and pathways used for candidate gene selection Table S3. Quality of sequencing reads per sample Table S4. Post-QC quality per sample Table S5. Replication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d7f6e43ffa601f9d5a68422bda7d13a
https://doi.org/10.1158/1078-0432.22464992
https://doi.org/10.1158/1078-0432.22464992
Autor:
Alan P. Venook, Sui Zhang, Erin L. Van Blarigan, Edward Giovannucci, Donna Niedzwiecki, Mingyang Song, Alexander Hantel, Fang-Shu Ou, Shuji Ogino, James N. Atkins, Leonard B. Saltz, Al B. Benson, Charles S. Fuchs, Robert J. Mayer, Jeffrey A. Meyerhardt
Publikováno v:
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol 27, iss 10
Background: Higher intake of long-chain ω-3 polyunsaturated fatty acids and nuts, rich plant sources of unsaturated fats, after colon cancer diagnosis are associated with improved survival. It is not known whether the amount or the distribution of o
Autor:
Kouros Owzar, Bryan P. Schneider, Donna Niedzwiecki, Yukihide Momozawa, Megan Li, Heinz-Josef Lenz, Chen Jiang, Michiaki Kubo, Flora Mulkey, Deanna L. Kroetz, Paula N. Friedman, Howard L. McLeod, Fei Shen, Alan P. Venook, William Kevin Kelly, Susan Halabi, Bert H. O'Neil, Howard S. Hochster, Federico Innocenti, Mark J. Ratain, Hope S. Rugo, James N. Atkins
Publikováno v:
Clinical Cancer Research. 24:4734-4744
Purpose: Bevacizumab is a VEGF-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of multiple cancers. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy or
Autor:
Brendan Guercio, Sui Zhang, Alan P. Venook, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Hanna Sanoff, Michelle R. Mahoney, Bert H. O'Neil, James E. Shaw, Blase N. Polite, Howard S. Hochster, James N. Atkins, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Charles S. Fuchs, Jeffrey A. Meyerhardt
Publikováno v:
Cancer Research. 79:3285-3285
Background: In non-metastatic colorectal cancer, a body mass index (BMI) paradox is observed where overweight and early obese patients experience improved outcomes compared to patients with normal, low, or morbidly obese BMI. The influence of obesity
Autor:
SS Grubs, J. A. Ellerton, Hyman B. Muss, Marie E. Wood, F. Kingsley, James N. Atkins, Judy Garber
Publikováno v:
Cancer Research. 71:P3-11
Statins have been shown in epidemiological and laboratory studies to have breast cancer risk reduction properties. We evaluated the effect of atorvastatin on breast mammographic density (MD) and other breast cancer biomarkers in a small randomized pl
Autor:
Adam Brufsky, Howard M. Gross, Paul T. Adams, Charles E. Geyer, Priya Rastogi, Rita S. Mehta, Rakesh Gaur, Richard G. Margolese, Francis M. Senecal, André Robidoux, Soonmyung Paik, Sandra M. Swain, James N. Atkins, Gong Tang, James A. Young, Harry D. Bear, Norman Wolmark, Joseph P. Costantino, Qing Liu, Eleftherios P. Mamounas, Luis Baez-Diaz, Louis Fehrenbacher
Publikováno v:
Cancer Research. 75:PD2-1
Purpose The NSABP B-40 study was designed to determine whether the addition of capecitabine (X) or gemcitabine (G) to neoadjuvant docetaxel (T) followed by AC increased pathologic complete response (pCR) rates and improved outcomes of women with oper
Autor:
EP Winer, Silvana Martino, Donald A. Berry, James N. Atkins, E. A. Perez, C. Cirrincione, Clifford A. Hudis, Ruth O'Regan, HP Becker, Lawrence N. Shulman
Publikováno v:
Cancer Research. 70:S6-3
Background: Four cycles of chemotherapy are frequently used as standard adjuvant chemotherapy for patients with low-risk primary breast cancer, though other regimens such as CAF, CMF, and TAC frequently are given for 6 cycles. Using a phase 3 factori